45 Participants Needed

Gemcitabine + Trastuzumab + Pertuzumab for Breast Cancer

Recruiting at 4 trial locations
Age: 18+
Sex: Female
Trial Phase: Phase 2
Sponsor: Memorial Sloan Kettering Cancer Center
Must be taking: Trastuzumab, Pertuzumab
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a combination of three drugs to treat advanced HER2 positive breast cancer in women who have already tried other treatments. The combination includes a chemotherapy drug called gemcitabine and two drugs, trastuzumab and pertuzumab, that stop cancer cells from growing. Pertuzumab was originally developed independently from trastuzumab and later found to work well together when combined with trastuzumab. The goal is to see if this new combination is more effective and safe.

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that patients should have progression of disease on their current therapy, which might imply a change in treatment.

Is the combination of Gemcitabine, Trastuzumab, and Pertuzumab safe for humans?

The combination of Trastuzumab and Pertuzumab, often used with chemotherapy, has been studied for safety in treating HER2-positive breast cancer. Common side effects include diarrhea, rash, and nasopharyngitis (cold-like symptoms), but no new safety concerns were identified in recent studies. Continuous monitoring of Pertuzumab's safety is recommended.12345

How is the drug combination of Gemcitabine, Trastuzumab, and Pertuzumab unique for breast cancer treatment?

This drug combination is unique because it combines Gemcitabine, a chemotherapy drug, with Trastuzumab and Pertuzumab, which are both targeted therapies that work together to block the HER2 protein on cancer cells, potentially enhancing the treatment's effectiveness against HER2-positive breast cancer.678910

What data supports the effectiveness of the drug combination Gemcitabine, Trastuzumab, and Pertuzumab for breast cancer?

Research shows that combining trastuzumab and pertuzumab with chemotherapy can improve survival rates in patients with HER2-positive breast cancer, as these drugs work together to block cancer cell growth more effectively than trastuzumab alone.246811

Who Is on the Research Team?

Chau T. Dang, MD - MSK Breast Medical ...

Chau Dang, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults with stage IV HER2-positive breast cancer who've had up to three prior chemotherapies in the metastatic setting and have previously been treated with trastuzumab + pertuzumab or pertuzumab-based therapy. Participants must have a good performance status, stable brain lesions if present, normal heart function, and acceptable blood counts and liver function. Pregnant individuals or those with severe past reactions to study drugs, hepatitis B/C, or recent serious heart issues cannot join.

Inclusion Criteria

My breast cancer is HER2 positive, confirmed by a lab test.
I am fully active and can carry on all my pre-disease activities without restriction.
I have been treated with trastuzumab and pertuzumab for my cancer.
See 8 more

Exclusion Criteria

I had a severe allergic reaction to trastuzumab or pertuzumab.
Pregnant patients
I have had hepatitis B or C in the past.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive gemcitabine, trastuzumab, and pertuzumab intravenously. Gemcitabine is administered weekly on days 1 and 8 every 3 weeks, trastuzumab every 3 weeks or weekly, and pertuzumab every 3 weeks.

3 months

Follow-up

Participants are monitored for safety and effectiveness after treatment using progression-free survival and response criteria.

2 years

What Are the Treatments Tested in This Trial?

Interventions

  • Gemcitabine
  • Pertuzumab
  • Trastuzumab
Trial Overview The trial is testing a combination of gemcitabine (a standard chemotherapy drug) with two targeted therapies—trastuzumab (Herceptin) and pertuzumab (Perjeta)—to see how effective they are against advanced HER2-positive breast cancer after previous similar treatments. It's a Phase II study focusing on effectiveness as well as safety.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Gemcitabine, Trastuzumab, and PertuzumaExperimental Treatment3 Interventions
The regimen will consist of gemcitabine at 1000mg/m\^2 IV weekly days 1 + 8 q 3 weeks + trastuzumab every 3 weeks (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose followed by 420 mg every 3 weeks), all given intravenously (IV). Trastuzumab may be given IV weekly (4 mg/kg loading dose followed by 2 mg/kg weekly) in lieu of the every 3 week schedule. A loading dose of trastuzumab will not be required for patients who have received it \< 6 weeks prior to Cycle 1 Day 1.

Gemcitabine is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Gemzar for:
  • Pancreatic cancer
  • Breast cancer
  • Ovarian cancer
  • Non-small cell lung cancer
🇺🇸
Approved in United States as Gemzar for:
  • Pancreatic cancer
  • Breast cancer
  • Ovarian cancer
  • Non-small cell lung cancer
🇨🇦
Approved in Canada as Gemzar for:
  • Pancreatic cancer
  • Breast cancer
  • Ovarian cancer
  • Non-small cell lung cancer
🇯🇵
Approved in Japan as Gemzar for:
  • Pancreatic cancer
  • Breast cancer
  • Ovarian cancer
  • Non-small cell lung cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+

Hoffmann-La Roche

Industry Sponsor

Trials
2,482
Recruited
1,107,000+
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Avastin, Herceptin, Rituxan, Accu-Chek
Dr. Levi Garraway profile image

Dr. Levi Garraway

Hoffmann-La Roche

Chief Medical Officer since 2019

MD from the University of Basel

Dr. Thomas Schinecker profile image

Dr. Thomas Schinecker

Hoffmann-La Roche

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University

Genentech, Inc.

Industry Sponsor

Trials
1,578
Recruited
569,000+
Ashley Magargee profile image

Ashley Magargee

Genentech, Inc.

Chief Executive Officer since 2024

MBA from Harvard University, BA from Princeton University

Levi Garraway profile image

Levi Garraway

Genentech, Inc.

Chief Medical Officer since 2021

MD, PhD

Hartford HealthCare

Collaborator

Trials
9
Recruited
1,300+

Published Research Related to This Trial

A study involving 808 patients with HER-2 positive breast cancer showed that adding pertuzumab to trastuzumab and docetaxel significantly improved overall survival, with a 3-year survival rate increase of 10% to 15%.
While pertuzumab did not worsen cardiac toxicity in patients with low cardiovascular risk, it was associated with increased side effects such as severe diarrhea and skin disorders, indicating the need for careful monitoring.
Pertuzumab. Promising for some women with metastatic breast cancer, but more assessment needed.[2016]
Pertuzumab, a new monoclonal antibody targeting HER2, has shown improved patient outcomes in clinical trials for early-stage and metastatic HER2-positive breast cancer, especially when used in combination with chemotherapy and trastuzumab.
The review highlights that while trastuzumab has improved survival for HER2-positive breast cancer, there is still a need for better treatment options, which pertuzumab aims to address, particularly for patients who continue to relapse.
Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.Lamond, NW., Younis, T.[2021]
Pertuzumab is an effective anti-HER2 monoclonal antibody that works by preventing HER2 from forming heterodimers, which reduces tumor cell growth and survival, particularly in HER2-positive metastatic breast cancer.
In the phase III CLEOPATRA trial involving a combination of pertuzumab, trastuzumab, and docetaxel, patients experienced significantly improved progression-free survival and overall survival compared to those receiving placebo, with an acceptable safety profile.
Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.McCormack, PL.[2021]

Citations

Pertuzumab. Promising for some women with metastatic breast cancer, but more assessment needed. [2016]
Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations. [2021]
Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer. [2021]
Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. [2021]
Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer: a retrospective single-armed cohort study in China. [2022]
HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes. [2020]
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy. [2017]
A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS). [2023]
A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity. [2021]
Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. [2021]
Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security